Mirum Pharmaceuticals Q2 EPS $(1.94) Misses $(0.81) Estimate, Sales $37.50M Beat $30.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mirum Pharmaceuticals reported Q2 earnings with losses of $(1.94) per share, missing the analyst consensus estimate of $(0.81) by 139.51%. This is a 130.95% decrease from the same period last year. However, the company reported quarterly sales of $37.50 million, beating the analyst consensus estimate of $30.00 million by 24.99%, a 114.46% increase from last year.
August 04, 2023 | 2:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Mirum Pharmaceuticals reported a significant miss on its Q2 earnings per share but beat sales estimates. This mixed result could lead to uncertainty in the market.
Mirum Pharmaceuticals reported a larger than expected loss per share, which is a negative signal to investors. However, the company beat sales estimates, which is a positive signal. The mixed results could lead to uncertainty and volatility in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100